Eli Lilly Remains Well Positioned for Industry-Leading Growth, Buoyed by Cardiometabolic Drugs

Sector Director

Damien Conover

Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Revenue is the money generated from normal business operations. Gross Profit is revenue minus cost of goods sold. Operating Income is revenue minus cost of goods sold and other operating expenses.

Revenue

Gross Profit

Operating Income

Revenue & Operating Income

Net Income, also called net earnings, is calculated as revenue minus cost of goods sold, operating expenses, depreciation, interest, taxes, and other expenses.

Net Income

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Following a very steep patent cliff in 2014, Lilly's growth prospects have improved as the company is launching several new blockbusters and patent losses are fading.

Lilly's internal pipeline is well positioned to mitigate the patent losses during the next decade. The company tends to spend a low- to mid-20s percentage of its sales on financing the development efforts of new drugs, much higher than the high-teens industry average. The robust pipeline is a result of Lilly's strong commitment to research. We believe cardiometabolic drugs Mounjaro, Trulicity, and Jardiance and immunology drug Taltz along with cancer drug Verzenio hold the highest sales potential of Lilly's currently launched drugs. Further, pipeline drugs lebrikizumab (atopic dermatitis), mirikizumab (immunology), and donanemab (Alzheimer's) hold major blockbuster potential. 

Lilly's strong entrenchment in insulin production should also help the company deal with patent losses. Unlike traditional drugs, Lilly's insulin drugs are very hard to copy by generics and create barriers to entry for noninsulin producers because of the large up-front investments needed to create scale efficiencies. A new weekly insulin in late-stage development offers another avenue of growth in this mature market.

The company is taking a hard look at its bottom line. Through a combination of cost savings and expected top-line growth, Lilly aims to expand operating margins over the next several years, which we believe is achievable. Lilly expects to increase gross margins through productivity initiatives and greater capacity utilization. Overall, we view the strong traction of recently launched high-margin drugs in several indications as supporting the overall profitability gains.

Business Strategy & Outlook

Patents, economies of scale, and a powerful distribution network support Eli Lilly’s wide moat. Lilly's patent-protected drugs carry strong pricing power, which enables the firm to generate returns on invested capital in excess of its cost of capital. Further, the patents give the company time to develop the next generation of drugs before generic competition arises. Lilly’s diversified product portfolio means the company’s top drugs represent only a moderate amount of total sales, with the largest drug, Trulicity, representing almost 20% of total sales, which sets up manageable cash flow declines as new products mitigate the generic competition. Also, Lilly’s operating structure allows for cost-cutting after patent losses to reduce the margin pressure from lost high-margin drug sales. Overall, Lilly's established product line creates the enormous cash flows needed to fund the average $800 million in development costs per new drug. In addition, the company's powerful distribution network sets up the company as a strong partner for smaller drug companies that lack Lilly's resources. Lilly's entrenched insulin franchise creates an added layer of competitive advantage, as interchangeable insulin competition seems many years away due to the complexity of gaining generic approval for insulin and the high cost to build the needed economy of scale for insulin production. Also, Lilly's recently launched biologic drugs create higher hurdles over traditional small molecule for biosimilars to gain market share following the eventual patent expirations.

We think the firm does face environmental, social, and governance risks, particularly related to potential U.S. drug price-related policy reform (close to 60% of total sales are generated by prescription drugs sales in the U.S.) to increase access by lowering drug prices. Ongoing product governance issues (including litigation related to side effects and patents) also weigh on the company. While we have factored these threats into our analysis, we don't see them as material to our moat rating for Eli Lilly.

Wide

Economic Moat

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q2 2023

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

This week Lilly surpassed Johnson & Johnson to become the world's largest Pharma by market cap. That is quite astonishing given JNJ drove $95bn of revenues last year, compared to Lilly's $28bn. Pharma valuations are based on "jam tomorrow", however, and in Tirzepatide Lilly may have the world's first $100bn per annum selling drug.

Eli Lilly: Most Valuable Global Pharma Thanks To Tirzepatide's Mind-Blowing Possibilities

C3.ai

Mullen Automotive

NVIDIA

O'Reilly Automotive

Shopify

Figuring out which growth stocks to sell may be the last thing on your mind right now. After all, rising hopes for a pivot on interest rates by the Federal Reserve, plus secular growth trends such as accelerating adoption of artificial intelligence (or AI) have provided a massive boost for shares in fast-growing companies lately.

7 Growth Stocks to Sell in June Before They Crash and Burn

Eli Lilly & Co. LLY, +1.64% on Friday released new clinical trial data on treatments for certain types of early breast cancer and mantle cell lymphoma. New analysis from a late-stage trial of Verzenio in node-positive, high risk early breast cancer showed that the treatment in combination with endocrine therapy improved invasive disease-free survival rates by 5.9% in people 65 and older and 6.4% in patients under 65.

Eli Lilly releases new data on breast cancer, lymphoma treatments

New analyses from the Phase 3 monarchE trial of two years of Verzenio treatment in node-positive, high risk early breast cancer show similar efficacy across age groups and in patients who had dose adjustments with benefit maintained at four-year follow-up; overall quality of life during the Verzenio treatment period shown to be similar to endocrine therapy alone Updated data from the Phase 1/2 BRUIN trial of Jaypirca in patients with covalent BTK inhibitor pre-treated relapsed or refractory MCL continue to demonstrate durable efficacy and no newly identified safety signals INDIANAPOLIS , June 2, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Verzenio® (abemaciclib; CDK4/6 inhibitor) and Jaypirca™ (pirtobrutinib; non-covalent (reversible) BTK inhibitor) data to be presented at the 2023 ASCO® Annual Meeting in Chicago, June 2 – 6, 2023. Presentations include new analyses from the Phase 3 monarchE trial of two years of Verzenio treatment in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, high risk early breast cancer (EBC) and updated data from the Phase 1/2 BRUIN trial for an approved use of Jaypirca in patients with covalent BTK inhibitor pre-treated relapsed or refractory mantle cell lymphoma (MCL).

Lilly Highlights Verzenio® (abemaciclib) and Jaypirca™ (pirtobrutinib) Data at 2023 ASCO® Annual Meeting

Biogen

Medicare on Thursday announced plans for coverage of new Alzheimer's drugs whose accessibility has become a point of controversy.

Medicare unveils plan for coverage of new Alzheimer's drugs

Biogen stock jumped into a buy zone Thursday after Medicare officials said they would pay for some Alzheimer's treatments.

Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It

Johnson & Johnson

Novo Nordisk

Novartis

Roche Holding AG

Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Roche (RHHBY) and Novartis (NVS) are worth retaining in your portfolio.

5 Large Drug Stocks to Watch From a Thriving Industry

AI has taken the world by storm this year. The key reason is that AI might disrupt a wide variety of industries.

2 Newly Minted AI Stocks to Buy Right Now

INDIANAPOLIS , May 30, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the Goldman Sachs 44th Annual Global Healthcare Conference, June 12-13, 2023. Anat Ashkenazi, Lilly executive vice president and chief financial officer, will participate in a fireside chat on June 12 at 4:20 p.m.

Lilly to Participate in Goldman Sachs Global Healthcare Conference

Eli Lilly and Novo Nordisk have been two of the hottest dividend-paying pharma stocks of late. While both companies sport well-supported dividends, one company comes with inherently less risk and stronger growth prospects.

Better Dividend Stock: Eli Lilly or Novo Nordisk?

XtalPi said the drug candidates will target a disease that currently has no medicine available.

Sequoia China-Backed AI Startup Xtalpi To Partner With Pharma Giant Eli Lilly In $250 Million Novel Drug Deal

Broadcom

Radian Group

Assurant

FactSet Research Systems

NCR Corporation

Walmart

No, you read this correctly – we're here to discuss overvalued value stocks to sell. Seemingly a contradiction in terms, a company that becomes overvalued by nature is no longer a value play.

7 Overvalued Value Stocks to Sell Before June 2023

UnitedHealth Group

The trillion-dollar club is an exceedingly rare group. In fact, there are only 5 companies on that list currently.

3 High-Growth Stocks to Buy Before They Join the Trillion-Dollar Club

NEWARK, N.J.--(BUSINESS WIRE)---- $LLY #T1--Attorneys at Hagens Berman reached a settlement with Eli Lilly worth more than $500 million in a class-action lawsuit alleging overpricing of insulin.

Hagens Berman: Settlement Worth in Excess of $500 Million Reached in Insulin Pricing Class-Action Lawsuit

An analyst expects Lilly to launch a competitor in weight-loss drugs a year earlier than expected, giving Eli Lilly stock a chance to shine. The post Eli Lilly Could Launch Its Rival To Novo Nordisk's Weight-Loss Drug A Year Earlier Than Expected appeared first on Investor's Business Daily.

Eli Lilly Could Launch Its Rival To Novo Nordisk's Weight-Loss Drug A Year Earlier Than Expected

Pfizer

A national obsession with a new class of weight-loss drugs is turning dangerous, doctors and researchers say, as many patients are inappropriately prescribed Wegovy, Ozempic and similar medications and supply shortages generate a market for unauthorized, potentially risky copycat versions of these drugs.

The dark side of the weight-loss drug craze: Eating disorders, medication shortages, dangerous knock-offs

AbbVie

Looking at stock returns, Eli Lilly has outperformed AbbVie and the broader indices.

Should You Pick AbbVie Stock Over LLY?

Cue Biopharma

Viking Therapeutics

Now is a great time to start accumulating top biotech stocks. The biotech boom is red-hot.

3 Biotech Stocks Sitting on Huge-Upside Catalysts

The best-performing US big cap biopharma company this year still has lots of room to grow, according to brokers. Eli Lilly and Co (NYSE:LLY) “still offers one of the cleanest, de-risked growth stories” in the large cap pharmaceutical space, UBS analysts wrote in a note this week.

Eli Lilly is the best-performing big cap pharma stock this year for a reason, analysts say

Eli Lilly & Co (NYSE: LLY) has rallied over the past three months but a Bank of America analyst says it's not out of room to run just yet.

Eli Lilly stock price forecast ahead of obesity drug approval

Amazon

Alphabet

ServiceNow

Merck

As someone who has been writing about stocks professionally for 18 years, I remember when Microsoft (NASDAQ: MSFT ), Amazon (NASDAQ: AMZN ) and Apple (NASDAQ: AAPL ) were the first companies with $1 trillion market capitalizations. There was a great deal of fascination with the milestones at the time.

7 Stocks That Could Be the Next $2 Trillion-Dollar Companies

Cigna

DexCom

Elevance Health Inc

Exact Sciences

Humana

The Baron Health Care Fund's first five years have been exceptional in every sense of the word. Launched in spring 2018, the fund has navigated around the COVID-19 pandemic, a biotech initial public offering market that boomed and fizzled, and D.C.

These stock pickers led the health-fund category over the past 5 years. Here's where they're investing now.

Reduced greenhouse gas emissions by 20% Improved access to Lilly insulins in the U.S. Nearly doubled patients reached in resource-limited settings through global health efforts INDIANAPOLIS , May 22, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today released its latest Environmental, Social and Governance (ESG) report showing progress towards the company's ambitious sustainability goals, which are critical to maintaining a strong and resilient company. Notable sustainability highlights in the report include: Reducing greenhouse gas emissions in the company's operations by more than 20% from 2020 to 2022 despite significant business growth over the same timeframe.

Lilly ESG Report Highlights Progress Towards Sustainability Goals

Capital One

Momentum stocks are securities that are rising fast and seeing their gains accelerate. This is often because a given stock has one or more catalysts that have led to a rally in its share price.

News for Eli Lilly Stock (LLY)